Conflict of interest:MYK is an inventor on patent US62/250,561 relating to methods for gene editing in hematopoietic stem cells to enhance the therapeutic efficacy of antigen-specific immunotherapy. MLC has employment/ownership/ equity and is a founder of Wugen, receives consultant fees from RiverVest, and receives royalties from NeoImmuneTech Inc. TAF is a consultant and has equity/royalties from Wugen; has research support from ImmunityBio, Affimed, Compass Therapeutics, and HCW Biologics; and is an advisor for Kiadis, Indapta, and Orca Biosystems. JFD has research support from Incyte Corporation and Bioline, receives consultant fees from RiverVest and NeoImmuneTech Inc., and has ownership/equity and is a founder of Wugen and Magenta.